消栓通絡(luò)顆粒對(duì)缺血性中風(fēng)風(fēng)痰瘀阻證的早期干預(yù)
發(fā)布時(shí)間：2019-07-26 21:31
【摘要】：目的:探討消栓通絡(luò)顆粒早期干預(yù)對(duì)缺血性中風(fēng)(風(fēng)痰瘀阻證)患者康復(fù)的療效,及對(duì)炎癥因子和神經(jīng)因子的影響。方法:將160例患者按SAS軟件生成的隨機(jī)按數(shù)字表法分為對(duì)照組和觀察組。兩組均參照指南給予綜合內(nèi)科處理和康復(fù)措施。對(duì)照組給予針刺和推拿的中醫(yī)康復(fù)措施,觀察組在對(duì)照組基礎(chǔ)加用消栓通絡(luò)顆粒,12 g/次,3次/d,溫開水沖服。兩組療程均為4周。分別于治療前、治療后7,14,28 d進(jìn)行美國(guó)國(guó)立衛(wèi)生院神經(jīng)功能缺損(NIHSS)評(píng)分評(píng)價(jià);采用功能獨(dú)立性評(píng)定量表(FIM)評(píng)定日常生活活動(dòng)能力,采用四肢簡(jiǎn)化Fugl-Meyer功能量表(FMA)評(píng)價(jià)肢體的功能活動(dòng),致殘/病死情況采用Rankin修訂量表(mRS)評(píng)價(jià);檢測(cè)治療前后可溶性黏附分子-1(SICAM-1),高敏C反應(yīng)蛋白(hs-CRP),白細(xì)胞介素-6(IL-6),腫瘤壞死因子-α(TNF-α),S100-β蛋白(S100-β),血管生成素(ANG-1)和內(nèi)皮素-1(ET-1)水平。并進(jìn)行安全性評(píng)價(jià)。結(jié)果:觀察組疾病療效總有效率為89.47%,優(yōu)于對(duì)照組的77.03%(χ~2=4.182,P0.05);經(jīng)重復(fù)測(cè)量的方差分析,治療后兩組患者NIHSS評(píng)分均呈下降趨勢(shì)(F_(對(duì)照)=7.026,F_(觀察)=7.683,P0.05),治療后14 d和28 d觀察組NIHSS評(píng)分均低于對(duì)照組(P0.05,P0.01);治療后觀察組FIM和Fugl-Meyer(上、下肢)評(píng)分及總分均高于對(duì)照組(P0.01);治療后觀察組PRO量表癥狀、心理維度評(píng)分及總分均低于對(duì)照組(P0.01);經(jīng)秩和檢驗(yàn),觀察組致殘/病死情況輕于對(duì)照組(P0.05);治療后觀察組血清SICAM-1,hs-CRP,IL-6和TNF-α水平均低于對(duì)照組(P0.01);治療后觀察組血清S100-β,ANG-1和ET-1水平低于對(duì)照組(P0.01)。結(jié)論:在綜合治療方案中,消栓通絡(luò)顆粒能減輕致殘程度和提高患者和臨床療效,并能抑制SICAM-1,hs-CRP,IL-6和TNF-α炎癥因子表達(dá),調(diào)節(jié)S100-β,ANG-1和ET-1因子,起到減輕炎癥反應(yīng),保護(hù)神經(jīng)細(xì)胞,促進(jìn)神經(jīng)功能康復(fù)的作用。
[Abstract]:Objective: to investigate the effect of early intervention of Xiaoshuan Tongluo granule on rehabilitation of patients with ischemic apoplexy (wind-phlegm stasis syndrome) and its effect on inflammatory factors and neural factors. Methods: 160 patients were randomly divided into control group and observation group according to the method of digital table generated by SAS software. Both groups were given comprehensive medical treatment and rehabilitation measures according to the guidelines. The control group was given traditional Chinese medicine rehabilitation measures of acupuncture and massage, while the observation group was treated with Xiaoshuan Tongluo granule, 12 g / time, 3 times / d, warm boiled water and flushing in the control group. The course of treatment in both groups was 4 weeks. The (NIHSS) score of neurological deficit was evaluated at 7, 14 and 28 days after treatment, the activity of daily living was evaluated by functional independence scale (FIM), the functional activity of limbs was evaluated by limb simplified Fugl-Meyer function scale (FMA), and the disability / death rate was evaluated by Rankin revised scale (mRS) before treatment, 14 days after treatment, 28 days after treatment, (FIM) was used to evaluate the ability of daily living, (FMA) was used to evaluate the functional activity of limbs, and the disability / death rate was evaluated by Rankin revised scale (mRS). The levels of soluble adhesion molecule-1 (SICAM-1), high sensitivity C-reactive protein (hs-CRP), IL-6 (IL-6), tumor necrosis factor-偽 (TNF- 偽), S100-尾 protein (S100-尾), angiogenin (ANG-1) and endothelin-1 (ET-1) were measured before and after treatment. The security evaluation was carried out. Results: the total effective rate of the observation group was 89.47%, which was better than that of the control group (77.03%). After repeated analysis of variance, the NIHSS score of the two groups showed a downward trend (F_ (control) = 7.026, F_ (observation) = 7.683, P 0.05), and the NIHSS score of the observation group was lower than that of the control group on the 14th and 28th day after treatment (P0.05, P0.01). After treatment, the scores and total scores of FIM and Fugl-Meyer (upper and lower limbs) in the observation group were higher than those in the control group (P 0.01). After treatment, the symptoms, psychological dimension score and total score of the observation group were lower than those in the control group (P 0.01). After rank sum test, the disability / death rate in the observation group was lighter than that in the control group (P 0.05). After treatment, the levels of serum SICAM-1,hs-CRP,IL-6 and TNF- 偽 in the observation group were lower than those in the control group (P 0.01). After treatment, the levels of serum S 100-尾, ANG-1 and ET-1 in the observation group were lower than those in the control group (P 0.01). Conclusion: Xiaoshuan Tongluo granule can reduce the degree of disability and improve the clinical efficacy, inhibit the expression of SICAM-1,hs-CRP,IL-6 and TNF- 偽 inflammatory factors, regulate S100-尾, ANG-1 and ET-1 factors, play an important role in reducing inflammatory reaction, protecting nerve cells and promoting the rehabilitation of nerve function.
【作者單位】： 河北省中醫(yī)院黨校分院;
【基金】：河北省中醫(yī)藥管理局科研計(jì)劃項(xiàng)目(2012031)
【分類號(hào)】：R277.7
[Abstract]:Objective: to investigate the effect of early intervention of Xiaoshuan Tongluo granule on rehabilitation of patients with ischemic apoplexy (wind-phlegm stasis syndrome) and its effect on inflammatory factors and neural factors. Methods: 160 patients were randomly divided into control group and observation group according to the method of digital table generated by SAS software. Both groups were given comprehensive medical treatment and rehabilitation measures according to the guidelines. The control group was given traditional Chinese medicine rehabilitation measures of acupuncture and massage, while the observation group was treated with Xiaoshuan Tongluo granule, 12 g / time, 3 times / d, warm boiled water and flushing in the control group. The course of treatment in both groups was 4 weeks. The (NIHSS) score of neurological deficit was evaluated at 7, 14 and 28 days after treatment, the activity of daily living was evaluated by functional independence scale (FIM), the functional activity of limbs was evaluated by limb simplified Fugl-Meyer function scale (FMA), and the disability / death rate was evaluated by Rankin revised scale (mRS) before treatment, 14 days after treatment, 28 days after treatment, (FIM) was used to evaluate the ability of daily living, (FMA) was used to evaluate the functional activity of limbs, and the disability / death rate was evaluated by Rankin revised scale (mRS). The levels of soluble adhesion molecule-1 (SICAM-1), high sensitivity C-reactive protein (hs-CRP), IL-6 (IL-6), tumor necrosis factor-偽 (TNF- 偽), S100-尾 protein (S100-尾), angiogenin (ANG-1) and endothelin-1 (ET-1) were measured before and after treatment. The security evaluation was carried out. Results: the total effective rate of the observation group was 89.47%, which was better than that of the control group (77.03%). After repeated analysis of variance, the NIHSS score of the two groups showed a downward trend (F_ (control) = 7.026, F_ (observation) = 7.683, P 0.05), and the NIHSS score of the observation group was lower than that of the control group on the 14th and 28th day after treatment (P0.05, P0.01). After treatment, the scores and total scores of FIM and Fugl-Meyer (upper and lower limbs) in the observation group were higher than those in the control group (P 0.01). After treatment, the symptoms, psychological dimension score and total score of the observation group were lower than those in the control group (P 0.01). After rank sum test, the disability / death rate in the observation group was lighter than that in the control group (P 0.05). After treatment, the levels of serum SICAM-1,hs-CRP,IL-6 and TNF- 偽 in the observation group were lower than those in the control group (P 0.01). After treatment, the levels of serum S 100-尾, ANG-1 and ET-1 in the observation group were lower than those in the control group (P 0.01). Conclusion: Xiaoshuan Tongluo granule can reduce the degree of disability and improve the clinical efficacy, inhibit the expression of SICAM-1,hs-CRP,IL-6 and TNF- 偽 inflammatory factors, regulate S100-尾, ANG-1 and ET-1 factors, play an important role in reducing inflammatory reaction, protecting nerve cells and promoting the rehabilitation of nerve function.
【作者單位】： 河北省中醫(yī)院黨校分院;
【基金】：河北省中醫(yī)藥管理局科研計(jì)劃項(xiàng)目(2012031)
【分類號(hào)】：R277.7
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 任彩霞;馮丙東;余永平;;急性腦梗死患者血清hs-CRP、IL-6和TNF-α測(cè)定及其臨床意義[J];陜西醫(yī)學(xué)雜志;2016年11期
2 譚志勇;;急性腦卒中患者血清炎癥細(xì)胞因子水平變化及臨床意義[J];西南國(guó)防醫(yī)藥;2016年10期
3 魏戌;謝雁鳴;常艷鵬;鄒憶懷;趙性泉;韓艦華;王新志;馬云枝;畢齊;解慶凡;趙建軍;曹曉嵐;陳紅霞;王詩(shī)忠;閆詠梅;韓祖成;易丹輝;王永炎;;中醫(yī)藥干預(yù)缺血性中風(fēng)病3年隨訪結(jié)局評(píng)價(jià)[J];中華中醫(yī)藥雜志;2016年10期
4 廖穆熙;潘海華;莊禮興;賀君;畢文卿;林涵;;以攣三針為主穴治療中風(fēng)后痙攣性癱瘓[J];長(zhǎng)春中醫(yī)藥大學(xué)學(xué)報(bào);2016年03期
5 ;中國(guó)腦梗死急性期康復(fù)專家共識(shí)[J];中華物理醫(yī)學(xué)與康復(fù)雜志;2016年01期
6 王瑩;y囇，
本文編號(hào)：2519816
本文鏈接：http://www.wukwdryxk.cn/zhongyixuelunwen/2519816.html
最近更新
教材專著
